× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics

Year : 2015   |  Volume : 3   |  Issue : 3   |   Page : 53-64  

Optimization And Development Of Candesartan Cilexetil Loaded Solid Lipid Nanoparticle for The Treatment of Hypertension

S. S. Kamble, M. S. Gambhire, K. N. Gujar

Correspondence Address:Sinhgad College of Pharmacy, Pune, India

Source of Support: , Conflict of Interest: None

DOI: 10.4103/2231-4040.197331


Candesartan is an angiotensin-receptor blocker (ARB) that is used to treat hypertension. However, poor aqueous solubility and poor oral bioavailability has limited therapeutic applications of Candesartan. We formulated solid lipid nanoparticles of Candesartan cilexetil by using high speed homogenization followed by probe sonication. The solid lipid nanoparticles were evaluated for particle size analysis, entrapment efficiency, zeta potential, and in vitro drug release. The resultant solid lipid nanoparticles had a mean size of 87.7nm and entrapment efficiency of 80.46 %. Zeta potential was found to be -31 mV, it shows that the formulation is stable. The SEM studies indicated smooth and spherical shape nanoparticle. The in vitro drug release study by dialysis method indicated that drug entrapped in the solid lipid nanoparticle remains entrapped at acidic pH and in phosphate buffer of pH 6.8, drug is released in a controlled manner for a prolonged period of time as compared to plain drug and marketed preparation. All these findings reinforce the fact that Candesartan solid lipid nanoparticles are promising novel delivery system

Keywords: Solid lipid nanoparticles, candesartan, oral bioavailability, lymphatic transport

How to cite this article: